Swiftmerge Acquisition in a proxy filing seeks shareholder approval of an extension that would move the SPAC’s deal deadline from June 17 to March 15, 2024.
Swiftmerge last month said it signed a non-binding letter of intent for a business combination with HDL Therapeutics, a privately held commercial stage biotech company.
HDL has an FDA-approved cardiovascular therapy for reducing coronary atheroma in homozygous familial hypercholesterolemia patients.
The SPAC holds about $225 million in trust. Read more.
